- Trial phase
- Approved
- Time to market
- Already FDA-approved (September 25, 2026). Teva plans to launch DEGEVMA commercially in the coming months.
- Why 4/10
- DEGEVMA was already approved by the FDA on September 25, 2026, with no pending PDUFA, pivotal readout, or AdComm scheduled. As an approved biosimilar in a crowded market at a large diversified pharma company, there is no hard binary catalyst in the next ~12 months, capping the impact score at 4.
DEGEVMA is already FDA-approved (Sep 25, 2026) with no upcoming binary regulatory catalyst. Watch for Teva's commercial launch timing and market-share capture in a crowded denosumab biosimilar field (10+ rivals). Teva's Q3 2026 earnings (reported Nov 3, 2026) may provide launch and revenue commentary.
Price Chart
Executive Summary
DEGEVMA (denosumab-adet) is Teva Pharmaceutical's FDA-approved biosimilar to Amgen's Xgeva (denosumab), cleared on September 25, 2026 for preventing bone complications in advanced cancer, treating giant cell tumor of bone, and hypercalcemia of malignancy. It is designated as interchangeable with the reference product. DEGEVMA is Teva's second denosumab biosimilar approved in 2026, alongside Ponlimsi (a Prolia biosimilar approved March 2026), giving Teva a complete denosumab portfolio. However, the US market is intensely competitive with at least 10 denosumab biosimilars already approved. Teva plans to launch both products in the coming months. As an already-approved drug at a large, diversified pharma company ($4.4B quarterly revenue) with no pending binary catalyst, DEGEVMA is a modest commercial contributor rather than a stock-moving event.
How It Works
DEGEVMA is a biosimilar (a near-identical copy) of Amgen's Xgeva (denosumab). Denosumab is a monoclonal antibody that blocks a protein called RANKL, which is involved in bone breakdown. By inhibiting RANKL, it helps prevent bone complications (fractures, spinal cord compression) in cancer that has spread to bone, treats giant cell tumor of bone, and treats hypercalcemia of malignancy (dangerously high calcium levels caused by cancer).
Trial Status
DEGEVMA received FDA approval on September 25, 2026 under BLA 761481 as a biosimilar to Xgeva (denosumab) via the 351(k) pathway. The approval was supported by comprehensive analytical, preclinical, and clinical data demonstrating comparable quality, safety, and efficacy to the reference product. The FDA also designated it as interchangeable with Xgeva.
The Two-Sided Case
Upcoming Catalysts
- Commercial launch timing and initial market share data for DEGEVMA and Ponlimsi
- Teva Q3 2026 earnings call (Nov 3, 2026) may provide biosimilar revenue and launch commentary
- Pricing and formulary placement updates in a competitive denosumab biosimilar market
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Teva Pharmaceutical Industries Ltd PRESS-RELEASE TEVA ·Originating report